Vyome Holdings (HIND) Capital Expenditures (2015 - 2023)
Vyome Holdings (HIND) posted quarterly Capital Expenditures of -$28000.0 for Q3 2023, down 165.12% year-over-year from $43000.0 in Q3 2022, and down 800.0% quarter-over-quarter from $4000.0 in Q2 2023.
Vyome Holdings (HIND) Capital Expenditures (2015 - 2023) Analysis & Trends
Vyome Holdings' Capital Expenditures history runs 9 years deep, the most recent figure standing at -$28000.0 for Q3 2023.
- In Q3 2023, Capital Expenditures fell 165.12% year-over-year to -$28000.0; the TTM figure through Dec 2023 stood at -$17000.0 (up 88.96% YoY), while the FY2023 annual figure was -$17000.0, down 383.33% from the prior year.
- Capital Expenditures for Q3 2023 stood at -$28000.0, down from $4000.0 in the prior quarter.
- The five-year high for Capital Expenditures was $413000.0 in Q4 2021, with the low at -$435000.0 in Q2 2021.
- The 5-year median for Capital Expenditures is $7000.0 (2022), against an average of $13473.7.
- Peak annual rise in Capital Expenditures reached 1741.67% in 2020, while the deepest fall reached 32100.0% in 2020.
- Vyome Holdings' Capital Expenditures stood at -$12000.0 in 2019, then jumped by 1741.67% to $197000.0 in 2020, then jumped by 109.64% to $413000.0 in 2021, then sank by 111.14% to -$46000.0 in 2022, then jumped by 39.13% to -$28000.0 in 2023.
- Business Quant data shows HIND's Capital Expenditures at -$28000.0 in Q3 2023, $4000.0 in Q2 2023, and $7000.0 in Q1 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 37.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 25.02 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 34.68 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -73.57 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 6.26 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 251.02 Mn |
| 10 | Vyome Holdings | 16.07 Mn | 8.18 Mn | 11,658.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2023 | -28,000.00 |
| Sep 30, 2023 | -28,000.00 |
| Jun 30, 2023 | 4,000.00 |
| Jun 30, 2023 | 4,000.00 |
| Mar 31, 2023 | 7,000.00 |
| Mar 31, 2023 | 7,000.00 |
| Dec 31, 2022 | -46,000.00 |
| Dec 31, 2022 | -46,000.00 |
| Sep 30, 2022 | 43,000.00 |
| Sep 30, 2022 | 43,000.00 |
| Jun 30, 2022 | -158,000.00 |
| Jun 30, 2022 | -158,000.00 |
| Mar 31, 2022 | 7,000.00 |
| Mar 31, 2022 | 7,000.00 |
| Dec 31, 2021 | 413,000.00 |
| Dec 31, 2021 | 413,000.00 |
| Sep 30, 2021 | -92,000.00 |
| Sep 30, 2021 | -92,000.00 |
| Jun 30, 2021 | -435,000.00 |
| Jun 30, 2021 | -435,000.00 |